Pharmacogenetics of cytotoxic drugs.
The main genetic polymorphisms affecting the metabolism and transport of cytotoxic drugs are discussed in this review. Likely future approaches to pharmacogenetics and emerging technologies, such as tumor classification using microarray analysis, are also considered.
Daly
A K
AK
Department of Pharmacological Sciences, University of Newcastle Medical School, Framlington Place, Newcastle-upon-Tyne, NE2 4HH, UK.
Hall
A G
AG
D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology*; D001191:Arylamine N-Acetyltransferase / Q000235:genetics / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D003603:Cytotoxins / Q000378:metabolism* / Q000494:pharmacology*; D004095:Dihydropyridines / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008780:Methyltransferases / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D010088:Oxidoreductases / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*
D000970:Antineoplastic Agents; D003603:Cytotoxins; D004095:Dihydropyridines; C038806:1,4-dihydropyridine; D003577:Cytochrome P-450 Enzyme System; D010088:Oxidoreductases; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D001191:Arylamine N-Acetyltransferase; D014453:Glucuronosyltransferase